Sökning: id:"swepub:oai:DiVA.org:uu-300034" >
Incidence, prevalen...
Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications : a nationwide study in Sweden, 2006-2013
-
- Norhammar, Anna (författare)
- Karolinska Institutet
-
- Bodegård, Johan (författare)
- Astra Zeneca Nord Balt, Sodertalje, Sweden.
-
- Nyström, Thomas (författare)
- Karolinska Institutet
-
visa fler...
-
- Thuresson, Marcus (författare)
- Statisticon AB, Uppsala, Sweden.
-
- Eriksson, Jan W. (författare)
- Uppsala universitet,Klinisk diabetologi och metabolism
-
- Nathanson, David (författare)
- Karolinska Institutet
-
visa färre...
-
Karolinska Institutet Astra Zeneca Nord Balt, Sodertalje, Sweden (creator_code:org_t)
- 2016-05-18
- 2016
- Engelska.
-
Ingår i: Diabetologia. - : Springer Science and Business Media LLC. - 0012-186X .- 1432-0428. ; 59:8, s. 1692-1701
- Relaterad länk:
-
https://link.springe...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Aims/hypothesis The global diabetes epidemic affects countries differently. We aimed to describe trends in the incidence and prevalence of type 2 diabetes mellitus requiring glucose-lowering treatment, together with associated life expectancy and risks of significant clinical complications. Methods Data on patients with type 2 diabetes who filled a prescription for any glucose-lowering drug (GLD) during the period 2006-2013 were extracted from the Swedish Prescribed Drug Register, Cause of Death Register and Swedish National Patient Register. Results In 2013, the prevalence of GLD-treated type 2 diabetes was 4.4% (n = 352,436) and the incidence was 399 per 100,000 population (n = 30,620). During 2006-2013, the prevalence increased by 61% while the incidence remained relatively stable; the prevalence of cardiovascular disease (CVD, 34% in 2013) and microvascular disease (16% in 2013) was also stable. Insulin use increased by 29% while sulfonylurea use declined by 55%. Compared with the general population, patients with type 2 diabetes had increased risk of myocardial infarction, stroke and all-cause mortality, with age-standardised risks of similar to 1.7-, 1.5- and 1.3-fold, respectively. These risks declined over time. Life-years lost due to diabetes was most pronounced at younger ages and improved in women over time from 2006 to 2013. Conclusions/interpretation The prevalence of type 2 diabetes requiring GLD treatment in Sweden increased substantially in recent years, while the incidence remained stable. Use of sulfonylurea declined while insulin use increased. The high prevalence of diabetes-related comorbidities, increased risk of complications and life-years lost highlights the need for optimised and new preventive strategies in patients with type 2 diabetes.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Nyckelord
- Cardiovascular disease
- Glucose-lowering therapy
- Incidence
- Life expectancy
- Mortality
- Prevalence
- Type 2 diabetes
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas